Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Truvada Sales To Rise On EU Okay In HIV Prevention; UK Use Uncertain

Executive Summary

The EU’s approval of Gilead’s Truvada for pre-exposure prophylaxis makes it the first medicine licensed in Europe to reduce the risk of HIV transmission through sexual intercourse and puts pressure on Britain’s reluctant, cash-strapped National Health Service to provide public funding for the drug’s preventative use.


Related Content

ViiV Poised To Take HIV PrEP Injectable In Late-Stage Trials
Hepatitis C And PrEP Bring More Funding Headaches For NHS England
France Leads Europe In Reimbursing Truvada For HIV Prophylaxis


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst